RNS Number: 3367D GSK PLC 15 February 2024

GSK plc (the 'Company') <u>Vesting of Deferred Annual Bonus Plan Deferred Bonus Awards and Sale of Ordinary Shares and American Depositary Shares</u>

This notification sets out the vesting details for Persons Discharging Managerial Responsibilities ('PDMRs') of Deferred Bonus Awards over Ordinary Shares and American Depositary Shares ('ADSs') made in 2021 under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan ('DABP') and subsequent sale of Ordinary Shares and ADSs to meet tax liabilities. In accordance with the shareholder approved 2017 Remuneration Policy and the DABP rules, the awards comprised a mandatory bonus deferral only. The three-year restricted period for the awards commenced on 10 February 2021 and ended on 12 February 2024. Dividends accrued on the awards during the restricted period.

The awards were granted in 2021 as restricted awards over ADSs for US participants and as nil-cost options over Ordinary Shares for all other participants.

The closing prices of Ordinary Shares and of ADSs of GlaxoSmithKline plc on 12 February 2024 were £16.264 and \$41.07.

Transaction notification

1.	Details of PDMR/per	son closely associated with them ('PCA')
a)	Name	Emma Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer auctioneer or auction	, emission allowance market participant, auction platform, on monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transa (ii) each type of transaction(s) has be	ction(s): section to be repeated for (i) each type of instrument; saction; (iii) each date; and (iv) each place where sen conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s	Price(s) Volume(s)
		£0.00 52,435
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	
e)	Date of the	2024-02-12

ĺ		transaction		
	f)	Place of the transaction	N/A	

1.	Details of PDMR/pers	son closely associated with	them ('PCA')
a)	Name	Emma Walmsley	
b)	Position/status	Chief Executive Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio		et participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.		saction; (iii) each date; and	ated for (i) each type of instrument; d (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 31 1/4 pen- ISIN: GB00BN7SWP63	ce each ('Ordinary Shares')
b)	Nature of the transaction	The sale of Ordinary Shares a nil-cost option award grant Deferred Annual Bonus Plan	to meet tax liabilities on the exercise of ed in 2021 under the Company's 2017
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.5180	24,682
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2024-02-12	
f)	Place of the transaction	London Stock Exchange (XL	ON)

1.	Details of PDMR/p	erson closely associated with them ('PCA')
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issue auctioneer or auc	er, emission allowance market participant, auction platform, tion monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.		saction(s): section to be repeated for (i) each type of instrument; ansaction; (iii) each date; and (iv) each place where been conducted
a)	Description of the	American Depositary Shares ('ADSs')

,	financial instrument	ISIN: US37733W2044
b)	Nature of the transaction	The vesting of an award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) \$0.00 27,796
d)	information Aggregated volume	N/A (single transaction)
e)	Price Date of the	2024-02-12
	transaction	
f)	Place of the transaction	N/A

1.	Details of PDMP/por	son closely associated	with them ('BCA')		
1.	Details of PDIVIR/per	son closely associated	with them (PCA)		
a)	Name	Dr Hal Barron			
b)	Position/status	Non-Executive Director			
c)	Initial notification/ amendment	Initial notification			
2.	Details of the issuer auctioneer or auction		narket participant, auction platform,		
a)	Name	GSK plc			
b)	LEI	5493000HZTVUYLO1D793			
3.		saction; (iii) each date	epeated for (i) each type of instrument; ; and (iv) each place where		
a)	Description of the financial instrument	American Depositary Sh ISIN: US37733W2044	nares ('ADSs')		
b)	Nature of the transaction		et tax liabilities on the vesting of an award le Company's 2017 Deferred Annual Bonus		
c)	Price(s) and volume(s) Price(s)	Volume(s)		
		\$41.0648	14,941		
d)	Aggregated information	N/A (single transaction)			
	Aggregated volume Price				
e)	Date of the transaction	2024-02-12			
f)	Place of the transaction	New York Stock Exchai	nge (XNYS)		

1.	Details of PDMR/person closely associated with them ('PCA')

a)	Name	Diana Conrad		
b)	Position/status	Chief People Officer		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issue auctioneer or aucti		ce market participant, auction platform,	
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO	1D793	
3.	Details of the trans (ii) each type of tra transaction(s) has b	nsaction; (iii) each d	be repeated for (i) each type of instrument; ate; and (iv) each place where	
a)	Description of the financial instrument	Ordinary shares of 3 ISIN: GB00BN7SWF	11 ¼ pence each ('Ordinary Shares') P63	
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordin Shares granted in 2021 under the Company's 2017 Deferred And Bonus Plan and the subsequent exercise of the nil-cost option		
c)	Price(s) and volume(s	Price(s) £0.00	Volume(s) 7,600	
d)	Aggregated information	N/A (single transacti	on)	
	Aggregated volume Price			
e)		2024-02-12		

c)	transaction	2024-02-12
f)	Place of the transaction	N/A
		,
1.	Details of PDMR/per	son closely associated with them ('PCA')
a)	Name	Diana Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer auctioneer or auction	, emission allowance market participant, auction platform, on monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transa (ii) each type of tran transaction(s) has be	ction(s): section to be repeated for (i) each type of instrument; saction; (iii) each date; and (iv) each place where sen conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan

		£16.5104 4,083
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	
e)	Date of the transaction	2024-02-12
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/pers	SOI	n closely associated	with them ('PCA')	
a)	Name	Ja	mes Ford		
b)	Position/status	S۱	/P and Group Genera	Counsel, Legal and Comp	liance
c)	Initial notification/ amendment	lni	tial notification		
2.	Details of the issuer, auctioneer or auction			arket participant, auctio	n platform,
a)	Name	G	SK plc		
b)	LEI	54	93000HZTVUYLO1D7	93	
3.	Details of the transaction (ii) each type of transaction(s) has be	sa	ction; (iii) each date	epeated for (i) each type and (iv) each place whe	of instrument; ere
a)	Description of the financial instrument		rdinary shares of 31 ½	pence each ('Ordinary Sha	ares')
b)	Nature of the transaction	Sł	nares granted in 2021	n the form of a nil-cost opt under the Company's 2017 sequent exercise of the nil-	Deferred Annual
c)	Price(s) and volume(s)		Price(s)	Volume(s)	
			£0.00	9,157	
d)	Aggregated information	N	A (single transaction)		
	Aggregated volume Price				
e)	Date of the transaction	20	24-02-12		
f)	Place of the transaction	N/	Α		

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	James Ford	
b)	Position/status	SVP and Group General Counsel, Legal and Compliance	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issue	er, emission allowance market participant, auction platform,	

	auctioneer or auction monitor			
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D79	93	
3.	(ii) each type of trans	Details of the transaction(s): section to be repeated for (i) each type of instrument; ii) each type of transaction; (iii) each date; and (iv) each place where ransaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 1/4 ISIN: GB00BN7SWP63	pence each ('Ordinary Shares')	
b)	Nature of the transaction		res to meet tax liabilities on the exercise of ranted in 2021 under the Company's 2017 Plan	
c)	Price(s) and volume(s)	Price(s) £16.5056	Volume(s) 4,319	
d)	information Aggregated volume	N/A (single transaction)		
e)	Price Date of the transaction	2024-02-12		
f)	Place of the transaction	London Stock Exchange	(XLON)	

	Details of PDMR/per	Details of PDMR/person closely associated with them ('PCA')					
a)	Name	Sally Jackson					
b)	Position/status	SVP, Global Communications and CEO Office					
c)	Initial notification/ amendment	Initial notification	Initial notification				
2.	Details of the issuer auctioneer or auction	 emission allowance market on monitor	participant, auction plat	form,			
a)	Name	GSK plc					
b)	LEI	5493000HZTVUYLO1D793	493000HZTVUYLO1D793				
3.			iv) each place where	trument;			
3.	(ii) each type of tran	saction; (iii) each date; and (i	iv) each place where	trument;			
	(ii) each type of transaction(s) has be Description of the	een conducted Ordinary shares of 31 1/4 pence	each ('Ordinary Shares') orm of a nil-cost option ove the Company's 2017 Deferred	r Ordinary ed Annual			
a)	(ii) each type of trar transaction(s) has be Description of the financial instrument	en conducted Ordinary shares of 31 1/4 pence ISIN: GB00BN7SWP63 The vesting of an award in the fi Shares granted in 2021 under the Bonus Plan and the subsequential	each ('Ordinary Shares') orm of a nil-cost option ove the Company's 2017 Deferred	r Ordinary ed Annual			
a) b)	(ii) each type of trar transaction(s) has been bescription of the financial instrument Nature of the transaction	en conducted Ordinary shares of 31 ¼ pence ISIN: GB00BN7SWP63 The vesting of an award in the fi Shares granted in 2021 under the Bonus Plan and the subsequential	each ('Ordinary Shares') orm of a nil-cost option ove he Company's 2017 Deferent t exercise of the nil-cost option	r Ordinary ed Annual			
a) b)	(ii) each type of trar transaction(s) has been bescription of the financial instrument Nature of the transaction	ordinary shares of 31 ¼ pence ISIN: GB00BN7SWP63 The vesting of an award in the formula of the subsequent of the subseq	each ('Ordinary Shares') orm of a nil-cost option ove the Company's 2017 Deferrent exercise of the nil-cost option Volume(s)	r Ordinary ed Annual			

e)	Date of the transaction	2024-02-12
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Sally Jackson		
b)	Position/status	SVP, Global Communica	tions and CEO Office	
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, auctioneer or auction		arket participant, auction platform,	
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D79	3	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
a)	Description of the financial instrument	Ordinary shares of 31 ¼ p ISIN: GB00BN7SWP63	pence each ('Ordinary Shares')	
b)	Nature of the transaction		es to meet tax liabilities on the exercise of anted in 2021 under the Company's 2017 lan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		£16.5238	2,183	
d)	Aggregated information	N/A (single transaction)		
	Aggregated volume Price			
e)	Date of the transaction	2024-02-12		
f)	Place of the transaction	London Stock Exchange	(XLON)	

1.	Details of PDMR/p	erson closely associated with them ('PCA')
a)	Name	Luke Miels
b)	Position/status	Chief Commercial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issue auctioneer or auct	er, emission allowance market participant, auction platform, tion monitor
a)	Name	GSK plc
a) b)	Name LEI	GSK plc 5493000HZTVUYLO1D793

a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2021 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)	Price(s) Volume(s) £0.00 14,209
		. 14,209
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	
e)	Date of the transaction	2024-02-12
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')				
a)	Name	Lι	ıke Miels		
b)	Position/status	Cł	nief Commercial Officer		
c)	Initial notification/ amendment	lni	Initial notification		
2.	Details of the issuer, auctioneer or auctio			et participant, auction platform,	
a)	Name	G	SK plc		
b)	LEI	54	93000HZTVUYLO1D793		
3.	(ii) each type of tran	ils of the transaction(s): section to be repeated for (i) each type of instrument; ach type of transaction; (iii) each date; and (iv) each place where saction(s) has been conducted			
a)	Description of the financial instrument	Ordinary shares of 31 1/4 pence each ('Ordinary Shares') ISIN: GB00BN7SWP63			
b)	Nature of the transaction	a i		to meet tax liabilities on the exercise or ed in 2021 under the Company's 2017	
c)	Price(s) and volume(s))	Price(s) £16.5020	Volume(s) 166	
d)	Aggregated information	N	A (single transaction)		
	Aggregated volume Price				
e)	Date of the transaction	20	24-02-12		
f)	Place of the transaction	Lc	ondon Stock Exchange (XL	ON)	

a)	Name	Davi	id Redfern	
a)	Name	Davi	iu nediem	
b)	Position/status	Pres	sident Corporate Devel	opment
c)	Initial notification/ amendment	Initia	al notification	
2.	Details of the issuer, auctioneer or auctio			rket participant, auction platform,
a)	Name	GSł	< plc	
b)	LEI	5493000HZTVUYLO1D793		
3.	Details of the transaction (ii) each type of transaction(s) has be	saction(s): section to be repeated for (i) each type of instrument; ansaction; (iii) each date; and (iv) each place where been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 1/4 pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
b)	Nature of the transaction	Sha	res granted in 2021 ur	the form of a nil-cost option over Ordinary nder the Company's 2017 Deferred Annual equent exercise of the nil-cost option
c)	Price(s) and volume(s)) F	Price(s)	Volume(s)
		£	20.00	11,169
d)	Aggregated information	ΝA	(single transaction)	
	Aggregated volume Price			
e)	Date of the transaction	2024	4-02-12	
f)	Place of the transaction	N/A		

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	David Redfern	
b)	Position/status	President Corporate Development	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issue auctioneer or aucti	r, emission allowance market participant, auction platform, on monitor	
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.		action(s): section to be repeated for (i) each type of instrument; esaction; (iii) each date; and (iv) each place where een conducted	
a)	Description of the financial instrument	Ordinary shares of 31 1/4 pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
		ISIN. GEOODIN/SVF 03	
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2021 under the Company's 2017	

(c)	Price(s) and volume(s)	Price(s) £16.5152	Volume(s) 5,263
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2024-02-12	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Regis Simard		
b)	Position/status	President, Glob	bal Supply Chain	
c)	Initial notification/ amendment	Initial notification	on	
2.	Details of the issuer, auctioneer or auction		owance market pa	articipant, auction platform,
a)	Name	GSK plc		
b)	LEI	5493000HZTVU	JYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			for (i) each type of instrument; each place where
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
b)	Nature of the transaction	Shares granted	d in 2021 under the	m of a nil-cost option over Ordinary company's 2017 Deferred Annual exercise of the nil-cost option
c)	Price(s) and volume(s)	Price(s)		Volume(s)
		£0.00		8,414
d)	Aggregated information	N/A (single tran	nsaction)	
	Aggregated volume Price			
e)	Date of the transaction	2024-02-12		
f)	Place of the transaction	N/A		

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Regis Simard	
b)	Position/status	President, Global Supply Chain	
~)	Initial notification/	Initial notification	

U)	amendment	II IIII AI I IOUIIICAUOI I	
2.	Details of the issuer, auctioneer or auction		market participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D	793
3.		saction; (iii) each dat	repeated for (i) each type of instrument; e; and (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 31 1	4 pence each ('Ordinary Shares')
b)	Nature of the transaction		nares to meet tax liabilities on the exercise or granted in 2021 under the Company's 2017 Plan
c)	Price(s) and volume(s	Price(s) £16.4822	Volume(s) 3,969
d)	Aggregated information	N/A (single transaction	
	Aggregated volume Price		
e)	Date of the transaction	2024-02-12	
f)	Place of the transaction	London Stock Exchanç	ge (XLON)

a)	Name	Phil Thomson			
b)	Position/status	President, Global Affairs			
c)	Initial notification/ amendment	Initial notification			
2.	Details of the issuer, auctioneer or auction	l , emission allowance ma on monitor	rket participant, a	auction platform	٦,
a)	Name	GSK plc			
b)	LEI	5493000HZTVUYLO1D793	1		
3.		 ction(s): section to be rep saction; (iii) each date; a			nent;
	transaction(s) has be		na (IV) each plac	e wnere	
a)			. ,		
a) b)	transaction(s) has be Description of the	een conducted Ordinary shares of 31 ½ po	ence each ('Ordina the form of a nil-co der the Company's	ry Shares') est option over Ord 2017 Deferred A	nnual
,	transaction(s) has be Description of the financial instrument	Ordinary shares of 31 ½ pc ISIN: GB00BN7SWP63 The vesting of an award in Shares granted in 2021 un Bonus Plan and the subse	ence each ('Ordina the form of a nil-co der the Company's	ry Shares') est option over Ord 2017 Deferred A	nnual
b)	Description of the financial instrument Nature of the transaction	Ordinary shares of 31 1/4 pc ISIN: GB00BN7SWP63 The vesting of an award in Shares granted in 2021 un Bonus Plan and the subse	ence each ('Ordina the form of a nil-co der the Company's quent exercise of t	ry Shares') est option over Ord 2017 Deferred A	nnual

	Aggregated volume Price	
e)	Date of the transaction	2024-02-12
f)	Place of the transaction	N/A

1.	Details of PDMR/pers	son closely associated with the	m ('PCA')
a)	Name	Phil Thomson	
b)	Position/status	President, Global Affairs	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio	emission allowance market pa n monitor	rticipant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.		 ction(s): section to be repeated saction; (iii) each date; and (iv) een conducted	
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence earlsIn: GB00BN7SWP63	ach ('Ordinary Shares')
b)	Nature of the transaction	The sale of Ordinary Shares to me a nil-cost option award granted in Deferred Annual Bonus Plan	eet tax liabilities on the exercise of 2021 under the Company's 2017
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.4906	3,081
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2024-02-12	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/per	son closely associated with them ('PCA')
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer auctioneer or auction	, emission allowance market participant, auction platform, on monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793

3.		nsaction; (iii) each date; and (iv	d for (i) each type of instrument; /) each place where
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence of 31 1/4 pence	each ('Ordinary Shares')
b)	Nature of the transaction		rm of a nil-cost option over Ordinary e Company's 2017 Deferred Annual exercise of the nil-cost option
c)	Price(s) and volume(s) Price(s) £0.00	Volume(s) 13,426
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2024-02-12	
f)	Place of the transaction	N/A	

1.	Details of PDMR/pe	erson closely associated	with them ('PCA')
a)	Name	Deborah Waterhouse	
b)	Position/status	CEO, ViiV Healthcare ar	nd President, Global Health, GSK
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issue auctioneer or aucti		narket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D7	93
3.		nsaction; (iii) each date;	epeated for (i) each type of instrumen and (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 31 1/4 ISIN: GB00BN7SWP63	pence each ('Ordinary Shares')
,		ISIN: GB00BN7SWP63 The sale of Ordinary Sha	ares to meet tax liabilities on the exercise rranted in 2021 under the Company's 2017
a) b) c)	financial instrument Nature of the	ISIN: GB00BN7SWP63 The sale of Ordinary Sha a nil-cost option award of Deferred Annual Bonus I	ares to meet tax liabilities on the exercise rranted in 2021 under the Company's 2017
b)	financial instrument Nature of the transaction	ISIN: GB00BN7SWP63 The sale of Ordinary Sha a nil-cost option award of Deferred Annual Bonus Istorical Price(s)	ares to meet tax liabilities on the exercise ranted in 2021 under the Company's 2013 Plan Volume(s)
b) c)	financial instrument Nature of the transaction Price(s) and volume(s) Aggregated	ISIN: GB00BN7SWP63 The sale of Ordinary Sha a nil-cost option award of Deferred Annual Bonus Is) Price(s) £16.5186	ares to meet tax liabilities on the exercise ranted in 2021 under the Company's 2017 Plan Volume(s)
b)	financial instrument Nature of the transaction Price(s) and volume(s) Aggregated information Aggregated volume	ISIN: GB00BN7SWP63 The sale of Ordinary Sha a nil-cost option award of Deferred Annual Bonus Is) Price(s) £16.5186	ares to meet tax liabilities on the exercise ranted in 2021 under the Company's 2017 Plan Volume(s)

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHSFSFIIELSEDE